Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders
Sean P. Moran, James Maksymetz, P. Jeffrey Conn
Trends in Pharmacological Sciences (2019) Vol. 40, Iss. 12, pp. 1006-1020
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Role of Cholinergic Signaling in Alzheimer’s Disease
Zhi-Ru Chen, Jiabao Huang, Shu‐Long Yang, et al.
Molecules (2022) Vol. 27, Iss. 6, pp. 1816-1816
Open Access | Times Cited: 377
Impact of GPCR Structures on Drug Discovery
Miles Congreve, Chris de Graaf, Nigel A. Swain, et al.
Cell (2020) Vol. 181, Iss. 1, pp. 81-91
Open Access | Times Cited: 299
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches
Nicolaas I. Bohnen, Alison J. Yarnall, Rimona S. Weil, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 4, pp. 381-392
Open Access | Times Cited: 178
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Mingyang Zhang, Ting Chen, Xun Lu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 100
Inhaled Medicines: Past, Present, and Future
Sandra D. Anderson, Paul J. Atkins, Per Bäckman, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 48-118
Open Access | Times Cited: 77
A Biased View of μ-Opioid Receptors?
Alexandra E. Conibear, Eamonn Kelly
Molecular Pharmacology (2019) Vol. 96, Iss. 5, pp. 542-549
Open Access | Times Cited: 94
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Changiz Geula, Sara Dunlop, Ivan Ayala, et al.
Journal of Neurochemistry (2021) Vol. 158, Iss. 6, pp. 1394-1411
Open Access | Times Cited: 68
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
Colin Sauder, Luke Allen, Elizabeth Baker, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 63
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Samantha E. Yohn, Peter J. Weiden, Christian C. Felder, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1098-1112
Open Access | Times Cited: 60
Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases
Orkid Coskuner‐Weber, Ozan Mirzanli, Vladimir N. Uversky
Biophysical Reviews (2022) Vol. 14, Iss. 3, pp. 679-707
Open Access | Times Cited: 45
Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery
Timothy B. Callis, Taylor R. Garrett, Andrew P. Montgomery, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 13483-13504
Closed Access | Times Cited: 41
Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
Alan Breier, Stephen K. Brannan, Steven M. Paul, et al.
Psychopharmacology (2023) Vol. 240, Iss. 5, pp. 1191-1198
Open Access | Times Cited: 38
Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing
Isabella F. Orlando, James M. Shine, Trevor W. Robbins, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 149, pp. 105167-105167
Open Access | Times Cited: 31
The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases
Sarah E. Davis, Abagail B. Cirincione, Ana Catya Jiménez-Torres, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15340-15340
Open Access | Times Cited: 24
New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
Aineng Peng, Chai Jian-bo, Haiyuan Wu, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 607-620
Open Access | Times Cited: 10
A Systematic Review of Pesticide Exposure, Associated Risks, and Long-Term Human Health Impacts
Chander Shekhar, Reetu Khosya, Kushal Thakur, et al.
Toxicology Reports (2024) Vol. 13, pp. 101840-101840
Open Access | Times Cited: 10
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)
Martina Bortolami, Daniele Rocco, Antonella Messore, et al.
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 5, pp. 399-420
Closed Access | Times Cited: 46
PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders
Solveig Tiepolt, Philipp Meyer, Marianne Patt, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. Supplement 1, pp. 33S-44S
Open Access | Times Cited: 35
Astrocytes Mediate Cholinergic Regulation of Adult Hippocampal Neurogenesis and Memory Through M1 Muscarinic Receptor
Weipeng Li, Xiaohong Su, Neng-Yuan Hu, et al.
Biological Psychiatry (2022) Vol. 92, Iss. 12, pp. 984-998
Closed Access | Times Cited: 34
Cholinergic dysfunction in COVID-19: frantic search and hoping for the best
Eman Hassan Nadwa, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 396, Iss. 3, pp. 453-468
Open Access | Times Cited: 28
The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
Samantha E. Yohn, P.D. Harvey, Stephen K. Brannan, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 7
The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain
Caterina Montani, Carola Canella, Adam J. Schwarz, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 6, pp. 1194-1206
Open Access | Times Cited: 45
Mapping cryptic binding sites of drug targets to overcome drug resistance
Yangyang Gao, Wei‐Cheng Yang, Charles R. Ashby, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100934-100934
Closed Access | Times Cited: 15
Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis
Spyridon Siafis, Nobuyuki Nomura, Johannes Schneider‐Thoma, et al.
F1000Research (2025) Vol. 13, pp. 1017-1017
Open Access
Antimicrobial Neuropeptides and Their Receptors: Immunoregulator and Therapeutic Targets for Immune Disorders
Kaiqi Chen, Xiaojun Wu, Xiaoke Li, et al.
Molecules (2025) Vol. 30, Iss. 3, pp. 568-568
Open Access
Page 1 - Next Page

Scroll to top